MDxHealth SA (NASDAQ:MDXH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.6250.

A number of research analysts have commented on the company. TD Cowen reaffirmed a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. Lake Street Capital decreased their price objective on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Wall Street Zen lowered MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, William Blair downgraded MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th.

MDxHealth Price Performance

Shares of NASDAQ MDXH opened at $0.45 on Friday. The stock’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $2.54. MDxHealth has a one year low of $0.45 and a one year high of $5.33. The firm has a market cap of $22.50 million, a price-to-earnings ratio of -0.70 and a beta of 1.36.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. On average, equities analysts anticipate that MDxHealth will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MDXH. Mink Brook Asset Management LLC acquired a new stake in MDxHealth during the third quarter worth about $743,000. FreeGulliver LLC raised its position in shares of MDxHealth by 104.7% in the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after buying an additional 129,348 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of MDxHealth in the 3rd quarter valued at approximately $48,000. Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth during the 4th quarter worth approximately $68,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of MDxHealth during the 4th quarter worth approximately $83,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.